Truist Securities Reiterates Buy Rating on MBX Biosciences Inc (MBX): "We remain buyers of MBX following 4Q25 earnings"
Tweet Send to a Friend
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $50.00 price target on MBX Biosciences Inc (NASDAQ: MBX)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
